
From: Miller, Stefan Michael <stefan.miller@kirkland.com>
Sent: Thursday, September 21, 2017 6:46 PM
To: Trials
Cc: 'Danford, Andrew J'; Hollis, Amanda; *David.Cavanaugh@wilmerhale.com;
*Robert.gunther@wilmerhale.com; 'abrausa@durietangri.com';
*DDurie@durietangri.com; 'Pirozzolo, Lisa'; 'Prussia, Kevin S'; 'Allen, Owen';
#Pfizer_Genentech_IPRs
Subject: IPR2017-01488; IPR2017-01489

Dear PTAB Trials,

Petitioner in the above proceedings, Pfizer Inc., requests a conference call with the Board to seek authorization to:

- (1) correct a clerical error in Pfizer's Petition in IPR2017-01489, *i.e.*, the omission of claim 65 from the the box identifying Proposed Statutory Rejections of the '213 Patent for Grounds 1 and 2 (IPR2017-01489, Paper 1 at 5), notwithstanding detailed discussion of those grounds for claim 65 is provided in the body of the petition as Genentech acknowledged in its Preliminary Response (IPR2017-01489, Paper 7 at claim 51 n.8 (citing Paper 1 at 51-52)); and
- (2) file replies of no longer than fifteen (15) pages each to Genentech's Preliminary Responses in IPR2017-01488 and -01489 to address certain arguments and evidence submitted by Genentech in its attempt to swear behind certain prior art references.

Pfizer has conferred with counsel for Genentech, who indicated that it does not object to request (1) and does not take a position with respect to request (2) except that, to the extent that the Board grants a reply, Genentech believes that any reply should be no longer than 7 pages and that Genentech should be granted a sur-reply of equal length.

Counsel for Pfizer and Genentech are available for a conference call with the Board on Tuesday, September 26 between 12 and 2 ET. Please let us know if there are additional dates for which counsel should provide availability.

Regards,

Stefan M. Miller

KIRKLAND & ELLIS LLP
601 Lexington Avenue, New York, NY 10022
T +1 212 446 6479 M +1 917 455 4424
F +1 212 446 4900
Conf (US/Can) +18663311856,,,1838339505#
Conf (Int'l) +12819131081,,,1838339505#

stefan.miller@kirkland.com

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return email or by email to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all attachments.